Vuong Trieu - SEC Form 4 Insider Trading Activity

Summary

Updated Aug 3, 2026

Vuong Trieu has filed 4 SEC Form 4 filings across 1 company in the last 90 days - buying. Lifetime open-market purchases: $46K. Historical track record: 1/5 stars across 4 tracked purchases.

Profile

Vuong Trieu holds the role of CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc. (OTLC). Trieu has reported 10 insider filings with the SEC since 2024. The most recent filing was in July 2026.

RoleCHAIRMAN AND CEO, Director, 10% Owner
Notability50/100

Board memberships

Reported roles

Track Record

InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.

InsiderAlpha rating★☆☆☆☆ (1/5)
Total purchases tracked4
Purchases with forward-return data4
30-day win rate25%
90-day win rate100%
Avg 5-day return+3.57%
Avg 30-day return-6.76%
Avg 90-day return+62.46%
Best 30-day return+3.23%

Trading Pattern

InsiderAlpha's records for Vuong Trieu go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. The typical open-market purchase is $5K (10 buys totaling $46K). The largest single buy on record is $11K of OTLC in 2026. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.

Career & Filing History

Every role Vuong Trieu has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-07-02OTLCOncotelic Therapeutics, Inc.P - Open-market purchase240.0K$0.04$10K
2026-06-25OTLCOncotelic Therapeutics, Inc.P - Open-market purchase65.0K$0.04$3K
2026-06-25OTLCOncotelic Therapeutics, Inc.P - Open-market purchase75.0K$0.04$3K
2026-06-25OTLCOncotelic Therapeutics, Inc.P - Open-market purchase115.0K$0.04$5K
2026-06-17OTLCOncotelic Therapeutics, Inc.P - Open-market purchase96.0K$0.04$4K
2026-06-17OTLCOncotelic Therapeutics, Inc.P - Open-market purchase239.8K$0.04$11K
2025-07-08OTLCOncotelic Therapeutics, Inc.P - Open-market purchase94.7K$0.01$474
2025-07-08OTLCOncotelic Therapeutics, Inc.P - Open-market purchase1$0.01$0
2025-07-08OTLCOncotelic Therapeutics, Inc.P - Open-market purchase104.0K$0.01$520
2024-11-26OTLCOncotelic Therapeutics, Inc.P - Open-market purchase298.5K$0.03$9K

Companies - Last 90 Days

Other Insiders Active in the Same Stocks

Insiders who reported open-market trades at the companies Vuong Trieu has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.

More Notable Insiders

Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:

Frequently Asked Questions

Who is Vuong Trieu?

Vuong Trieu holds the role of CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc. (OTLC). Trieu has reported 10 insider filings with the SEC since 2024. The most recent filing was in July 2026.…

How many SEC Form 4 filings has Vuong Trieu submitted recently?

4 primary Form 4 filings in the last 90 days, covering 1 company.

Has Vuong Trieu been buying or selling stock?

Recorded transactions: 10 open-market purchases ($46K) and 0 open-market sales across all tracked filings.

How accurate is Vuong Trieu's historical track record?

Across 4 tracked purchases, Vuong Trieu averaged -6.8% avg 30-day return with a 25% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.

Where can I see all of Vuong Trieu's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Vuong Trieu profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.